Distinguishing Acute from Chronic and Resolved Hepatitis C Virus (HCV) Infections by Measurement of Anti-HCV Immunoglobulin G Avidity Index-Reference-Cited by-同舟云学术

Distinguishing Acute from Chronic and Resolved Hepatitis C Virus (HCV) Infections by Measurement of Anti-HCV Immunoglobulin G Avidity Index

Published:2007-10 Issue:10 Volume:45 Page:3400-3403
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Klimashevskaya S.¹²,Obriadina A.²,Ulanova T.²,Bochkova G.²,Burkov A.²,Araujo A.¹,Stramer Susan L.³,Tobler Leslie H.⁴,Busch Michael P.⁴,Fields Howard A.¹

Affiliation:

1. Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia

2. RPC Diagnostic Systems, Nizhniy Novgorod, Russia

3. American Red Cross Scientific Support Office, Gaithersburg, Maryland

4. Blood Systems Research Institute, San Francisco, California

Abstract

ABSTRACT An assay to measure avidity index (AI) was developed to diagnose incident hepatitis C virus (HCV) infections. The assay demonstrated an AI value statistically significantly lower in primary HCV infections than in chronic infections. When the assay was applied to past resolved infections, the difference in AI values was not as significant as the difference between incident and chronic infections. Lower AI values obtained in past resolved infections may be directly related to lower levels of immunoglobulin G anti-HCV in past resolved infections than in either new infections or chronic infections.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01012-07

Reference17 articles.

1. Brillanti, S., C. Masci, P. Ricci, M. Miglioli, and L. Barbara. 1992. Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C. J. Hepatol.15:998-1001.

2. Centers for Disease Control and Prevention. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly. Rep.47(RR-19):1-39.

3. Chang, J. C., B. Ruedinger, M.-E. Cong, S. Lambert, E. Lopareva, M. Purdy, B. P. Holloway, D. L. Jue, B. Ofenloch, H. A. Fields, and Y. E. Khudyakov. 1999. Artificial NS4 mosaic antigen of hepatitis C virus. J. Med. Virol.59:437-450.

4. Chau, K. H., G. J. Dawson, I. K. Mushahwar, R. A. Gutierrez, R. G. Johnson, R. R. Lesniewski, L. Mattsson, and O. Weiland. 1991. IgM-antibody response to hepatitis C virus antigens in acute and chronic post-transfusion non-A, non-B hepatitis. J. Virol. Methods35:343-352.

5. Chen, P. J., J. T. Wang, L. H. Hwang, Y. H. Yang, C. L. Hsieh, J. H. Kao, J. C. Sheu, M. Y. Lai, T. H. Wang, and D. S. Chen. 1992. Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection. Proc. Natl. Acad. Sci. USA89:5971-5975.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers in Detection of Hepatitis C Virus Infection;Pathogens;2024-04-17

2. Establishment of an anti-hepatitis C virus IgG avidity test for dried serum/plasma spots;Journal of Immunological Methods;2020-04

3. Immune responses to Mycobacterium tuberculosis membrane-associated antigens including alpha crystallin can potentially discriminate between latent infection and active tuberculosis disease;PLOS ONE;2020-01-31

4. Diagnosis of Human Immunodeficiency Virus Infection;Clinical Microbiology Reviews;2018-12-19

5. A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs;Eurosurveillance;2018-11-22